French pharma major Sanofi and US partner Regeneron Pharmaceuticals yesterday presented positive results from the EVEREST ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...

Chronic respiratory illnesses affect millions. Learn how PCPs can effectively manage asthma, COPD, and allergies through ...

In the EVEREST trial, 360 adults with severe, uncontrolled CRSwNP and coexisting asthma were randomized to receive Dupixent 300 mg (n=181) every two weeks or a weight- and immunoglobulin E (IgE ...

These are the first clinical study results for the drug in a large population of patients with darker skin tones ...

ABC delivered the most reach for pharma, thanks to its coverage of the NBA playoffs and world news broadcasts.

However, amid the broader macro uncertainty, the drug and biotech sector seems to have recovered in the past month, backed by ...

The specialty drug pipeline is robust with several new medications anticipated to gain approval in the coming years. Healthcare leaders need to be poised to have a deep understanding of the clinical ...

His diet used to come in a juice box. Now, at 24, he’s learning how to eat, taste, and enjoy food for the first time — on ...

Sanofi presents positive results from DISCOVER phase 4 study of Dupixent in atopic dermatitis patients with skin of colour at 2025 RAD conference: Paris Tuesday, June 10, 2025, 16 ...

Regeneron and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of Dupixent (dupilumab).

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...